2-[3-(4-Hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one | 1309608-35-2

• 分子结构分类: 有机化合物 - 木脂素、新木脂素和相关化合物 - 黄酮木脂素
• 英文名称: 2-[3-(4-Hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one
• CAS: 1309608-35-2
• 化学式: C₂₅H₂₂O₇
• 分子量: 434.445
• InChiKey: JSHOVYZEPZPJOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  94.4
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  反式-3-(4-羟基-3-甲氧基苯基)-2-丙烯-1-醇 在 盐酸 、 sodium periodate 、 四氧化锇 、 sodium acetate 、 sodium hydride 、 platinum(II) chloride 、 potassium hydroxide 、 silver(l) oxide 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 、 丙酮 、 苯 为溶剂， 反应 44.0h， 生成 2-[3-(4-Hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one
  参考文献：
  名称：

  Identification and initial SAR of silybin: An Hsp90 inhibitor

  摘要：

  Through Hsp90-dependent firefly luciferase refolding and Hsp90-dependent heme-regulated eIF2 alpha kinase (HRI) activation assays, silybin was identified as a novel Hsp90 inhibitor. Subsequently, a library of silybin analogues was designed, synthesized and evaluated. Initial SAR studies identified the essential, non-essential and detrimental functionalities on silybin that contribute to Hsp90 inhibition.[GRAPHICS]. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.088

文献信息

• FULVENE AND FULVALENE ANALOGS AND THEIR USE IN TREATING CANCERS
  申请人：Arbiser Jack L.

  公开号：US20080275016A1

  公开（公告）日：2008-11-06

  Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are fulvene and/or fulvalene analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, as well as numerous inflammatory, degenerative and vascular diseases, including various ocular diseases. Representative fulvene and/or fulvalene analogs include fulvene and fulvalene analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function, at least, by inhibiting Nox or ROS. In some embodiments, the Nox is one that is selectively expressed in cancer cells over normal cells, or one that is expressed in higher amounts in cancer cells over normal cells. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.
• US8841276B2
  申请人：——

  公开号：US8841276B2

  公开（公告）日：2014-09-23
• [EN] FULVENE AND FULVALENE ANALOGS AND THEIR USE IN TREATING CANCERS<br/>[FR] ANALOGUES DE FULVÈNE ET FULVALÈNE ET LEUR UTILISATION DANS LE TRAITEMENT DES CANCERS
  申请人：UNIV EMORY

  公开号：WO2008137740A1

  公开（公告）日：2008-11-13

  [EN] Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are fulvene and/or fulvalene analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, as well as numerous inflammatory, degenerative and vascular diseases, including various ocular diseases. Representative fulvene and/or fulvalene analogs include fulvene and fulvalene analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function, at least, by inhibiting Nox or ROS. In some embodiments, the Nox is one that is selectively expressed in cancer cells over normal cells, or one that is expressed in higher amounts in cancer cells over normal cells. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.
  [FR] L'invention concerne des composés, des compositions pharmaceutiques contenant ces composés, et des procédés de préparation et d'utilisation de ceux-ci. Ces composés consistent en des analogues de fulvène et/ou fulvalène. Ces composés et ces compositions peuvent être utilisés pour traiter et/ou prévenir une grande variété de cancers, notamment les cancers résistant aux médicaments, ainsi que de nombreuses maladies inflammatoires, dégénératives et vasculaires, de même que diverses maladies oculaires. Les analogues représentatifs de fulvène et/ou fulvalène consistent en des analogues de fulvène et fulvalène de divers colorants, hormones, sucres, peptides, oligonucléotides, acides aminés, nucléotides, nucléosides, et polyols. Ces composés semblent fonctionner, au moins, par inhibition de Nox ou des ROS. Dans certains modes de réalisation, le Nox est celui qui est sélectivement exprimé dans des cellules cancéreuses plutôt que dans les cellules normales, ou celui qui est exprimé en plus grandes quantités dans les cellules cancéreuses que dans les cellules normales. Ainsi, les composés consistent en de nouveaux agents thérapeutiques d'une variété de cancers et d'autres maladies.